US-based Electrical Geodesics (EGI) has received an investigational device exemption (IDE) from US Food and Drug Administration (FDA) to conduct clinical trials of its Geodesic Transcranial Electrical Neuromodulation (GTEN) device as a treatment for managing epilepsy.

The trials are designed to show the safety and feasibility of GTEN neuromodulation device in the management of epilepsy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Designed to evaluate and treat 20 patients, the initial trial in epilepsy is planned to be conducted at two centres, Harborview Hospital at Washington University and at the company’s own facility in Eugene under the direction of an external neurologist.

Following completion and based on results, the company will investigate routes to conduct pivotal studies and move towards clinical approval.

The FDA’s IDE enables the investigational device to be used in a clinical trial in order to collect safety and effectiveness data required to support a premarket notification or 510(k) submission.

See Also:

"The device delivers small amounts of highly targeted electrical current through a changing pattern of the device’s 256 electrodes to direct treatment to the focal area and spare treatment to non-target areas."

GTEN is the latest development of the company’s GES 400 dense-array EEG platform, and will use its advanced head modelling technologies to understand areas of the brain where treatment should be focused.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device delivers small amounts of highly targeted electrical current through a changing pattern of the device’s 256 electrodes to direct treatment to the focal area and spare treatment to non-target areas.

The company said during and after treatment the same device and electrodes can record brain activity to monitor safety and effects of the product.

Epilepsy is a life-threatening and debilitating condition where more than 25% of patients are drug refractory or resistant, where seizures result from electrical discharges, which frequently derive from a single source of abnormal or damaged brain tissue.

Most brain neuromodulation devices are contraindicated in epilepsy, as seizures might be induced rather than modulated or reduced.

According to research, well-directed magnetic or electrical stimulation can reduce the incidence of interictal spikes.